Physician profile
Troy Halteman
NPI 1689226573
$2,284.66
in general payments reported to CMS, 2019-2025
22 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.93 · 2022: $331 · 2023: $429 · 2024: $372 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,933.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $412.98 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $264.92 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $175.70 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $161.88 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.55 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.80 | 2023-2025 | Jardiance |
| Heartflow, INC. | $114.40 | 2024-2025 | |
| Scpharmaceuticals INC. | $106.29 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $100.35 | 2022-2024 | Winrevair, Verquvo |
| Impulse Dynamics (USA) INC. | $96.97 | 2023-2024 | Optimizer, Optimizer |
| Astrazeneca Pharmaceuticals Lp | $83.36 | 2023-2025 | Farxiga |
| Novo Nordisk INC | $80.74 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Actelion Pharmaceuticals US, INC. | $65.60 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $60.84 | 2022-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $48.50 | 2022-2023 | Xarelto |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $48.39 | 2023 | Barostim Neo System |
| Edwards Lifesciences Corporation | $47.61 | 2025 | |
| Daiichi Sankyo INC. | $29.40 | 2025 | Injectafer |
| Kestra Medical Technology Services, INC. | $25.71 | 2024 | Assure Wcd |
| Boston Scientific Corporation | $20.85 | 2024 | Watchman Flx |
| Mannkind Corporation | $19.93 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Halteman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.